Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

BTG licenses new prostate cancer drug to Cougar Biotechnology

BTG : 26 September, 2006  (Technical Article)
BTG, the global technology commercialisation company and Los Angeles-based Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced prostate cancer. BTG will receive an upfront cash payment and will benefit from further development milestones and a royalty on sales. Detailed financial terms were not disclosed.
BTG, the global technology commercialisation company and Los Angeles-based Cougar Biotechnology today announced that they have signed a licence agreement in which Cougar is granted worldwide exclusive rights to develop and commercialise abiraterone acetate, a potential novel therapeutic for treatment of advanced prostate cancer. BTG will receive an upfront cash payment and will benefit from further development milestones and a royalty on sales. Detailed financial terms were not disclosed.

Abiraterone was first synthesised at The Institute of Cancer Research in the UK as part of a BTG-funded programme to discover a potent, selective, orally active drug to inhibit the key enzyme in testosterone synthesis, 17ahydroxylase/C17,20-lyase. Suppression of testosterone synthesis was subsequently demonstrated in patients with prostate cancer.

Dr Roger Harrison, Vice President and Director of BTG’s Oncology Business Unit said, “We are very pleased to have secured a licensing partner with such a clear vision for the development and future clinical application of abiraterone acetate. This deal shows the value that we create for our partners, like ICR, and confirms that BTG is an important source of exciting new cancer drugs for the pharmaceutical industry.”

Dr. Arie Belldegrun, MD, FACS, Vice Chairman of the Board of Directors of Cougar Biotechnology said, “There is an urgent need for new and effective therapies for patients with advanced prostate cancer who fail first-line hormonal treatment. We believe that abiraterone could fill this void and serve as an important second-line hormonal agent.”

Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology added “We are pleased to be able to complete this licensing agreement with BTG for this novel, targeted therapy. We look forward to advancing the development of abiraterone.”

In the US, prostate cancer is the second leading cause of cancer death in men. Approximately one in six American men will develop prostate cancer at some time during their lifetime, and there are approximately 220,900 new cases each year. In the US, the annual death toll from prostate cancer is 28,900. The incidence of prostate cancer in the EU is approximately 142,000 and some 59,700 men die of the disease.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   Â© 2012 NewMaterials.com
Netgains Logo